Table 1.
Correlations of serglycin expression level with clinicopathologic features of breast cancer patients
| Patients | High SRGN (n = 30) | Low SRGN (n = 30) | P value |
|---|---|---|---|
| Age (years) | 0.78989 | ||
| ≥51 | 19 | 18 | |
| <51 | 11 | 12 | |
| Tumor size | 0.0034** | ||
| ≤2 cm | 7 | 16 | |
| >2 cm | 23 | 14 | |
| Chemoresistance | 0.00013** | ||
| No | 13 | 27 | |
| Yes | 17 | 3 | |
| Lymph node metastasis | 0.01485* | ||
| No | 6 | 15 | |
| Yes | 24 | 15 | |
| TNM stage | 0.00497** | ||
| I | 2 | 8 | |
| II | 6 | 10 | |
| III | 7 | 9 | |
| IV | 15 | 3 | |
| ER status | 0.05206* | ||
| Positive | 6 | 13 | |
| Negative | 24 | 17 | |
| PR status | 0.11805 | ||
| Positive | 10 | 18 | |
| Negative | 20 | 12 | |
| HER-2 status | 0.79576 | ||
| Positive | 15 | 14 | |
| Negative | 15 | 16 |
The relationship between SRGN expression and BC clinicopathological data was analyzed by chi-square test.
BC, breast cancer; ER, estrogen receptor; PR, progesterone receptor; SRGN, serglycin; TNM, tumor node metastasis.
*
P < 0.05.
**
P < 0.01.